V
Viridian Therapeutics Inc (VRDN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$29.80
-1.07 (-3.47%)
Market Cap: $3.51B
Last updated: Nov 17, 2026 at 11:05 AM ET
Viridian Therapeutics Inc (VRDN) Valuation Multiples
Viridian Therapeutics (VRDN) trades at 128.5x sales and 5.8x book value. Its P/S of 128.5x is above its 10-year median of 27.3x. Its forward P/E is 1.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 1.0x |
| Price to sales | 128.5x |
| Price to book | 5.8x |
| PEG | N/A |
| FCF yield | -10.2% |
Historical Medians
Against its 10-year medians, its P/B is 152.2% above 2.3x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 128.5x | N/A | 27.3x |
| P/B | 5.8x | 2.3x | 2.3x |
Valuation History
Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 2.0x in 2016 to 526.4x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $31.12 | 35.9x | 3.7x |
| 2024 | $19.17 | N/A | 2.3x |
| 2023 | $21.78 | N/A | 2.4x |
| 2022 | $29.21 | 526.4x | 3.0x |
| 2021 | $19.77 | 49.3x | 1.2x |
| 2020 | $16.45 | 49.2x | 0.5x |
| 2019 | $7.20 | 3.4x | 1.0x |
| 2018 | $45.43 | 10.1x | 1.8x |
| 2017 | $156.37 | 51.5x | 6.0x |
| 2016 | $75.11 | 2.0x | N/A |
Frequently Asked Questions About VRDN
What is VRDN's forward P/E ratio?
Viridian Therapeutics has a forward P/E ratio of 1.0x.
What is VRDN's price to sales ratio?
Viridian Therapeutics has a price to sales ratio of 128.5x.
VRDN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors